Lipitor partnership quids
Executive Summary
The Lipitor co-promotion agreement with Pfizer includes an option for Warner-Lambert to negotiate for co-promotion rights to Pfizer's droloxifene, darifenacin or Relpax (eletriptan), the contract states. Since the agreement was signed in June 1996, Pfizer has halted development of its breast cancer and osteoporosis candidate droloxifene. Darifenacin recently entered Phase III trials for the treatment of overactive bladder after development for irritable bowel syndrome was abandoned ("The Pink Sheet" Nov. 23, p. 7). Warner-Lambert and Pfizer signed a co-promotion letter of intent for Relpax in June, but the deal was not finalized at the time the competing merger proposals for Warner-Lambert were announced
|
The Lipitor co-promotion agreement with Pfizer includes an option for Warner-Lambert to negotiate for co-promotion rights to Pfizer's droloxifene, darifenacin or Relpax (eletriptan), the contract states. Since the agreement was signed in June 1996, Pfizer has halted development of its breast cancer and osteoporosis candidate droloxifene. Darifenacin recently entered Phase III trials for the treatment of overactive bladder after development for irritable bowel syndrome was abandoned ("The Pink Sheet" Nov. 23, p. 7). Warner-Lambert and Pfizer signed a co-promotion letter of intent for Relpax in June, but the deal was not finalized at the time the competing merger proposals for Warner-Lambert were announced. |